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Evaluation of the reporting quality of Randomized Controlled Trials for 
treatments in Multiple Myeloma published the last 5 years using the 
CONSORT 2010 statement. 
Ntellas Panagiotis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Randomized Clinical Trials 
The dissemination of biomedical information and publication of research results is integral to 
scientific endeavor and is closely linked with the historical development of the clinical trial [1]. Clinical 
trials come in all shapes and sizes, and the randomized controlled trial (RCT) resides within the 
hierarchy of clinical studies. In the 1970s, the FDA in the United States of America, passed mandate title 
21, requiring an RCT before a drug can be approved for sale.[5] Nowadays the randomized controlled 
trial sets the methodological standard of excellence in medical research and is widely accepted as the 
‘‘gold standard’’ by which the benefit of a pharmaceutical intervention is judged [2]. The reason why 
RCTs are considered the gold standard for establishing effectiveness is because they minimize bias in 
INTRODUCTION 
 
Abstract 
INTRODUCTION: Randomized Controlled Trials (RCTs) are the best tool to evaluate the 
effectiveness of clinical interventions. The Consolidated Standards of Reporting Trials 
(CONSORT) statement first introduced in 1996 and revised twice to its current form in 2010, is 
an evidence based approach to improve the reporting of randomized controlled trials. 
OBJECTIVE: Purpose of this study is to evaluate the completeness of reporting of RCTs 
published the last 5 years (from May 2011 to May 2016), testing therapeutic interventions for 
patients with Multiple Myeloma. 
METHODS: The electronic database PubMed was screened for RCTs, punished in English the last 
5 years, examining therapies for patients with Multiple Myeloma. Trials were considered eligible 
when participants were randomly assigned to at least two treatment arms. Completeness of 
reporting was assessed using the 2010 CONSORT checklist, which consists of 25 items with sub-
items (37 items in total). Response alternatives to each item in the checklist were: yes, no and 
not applicable. Primary end-point was the evaluation of the completeness of reporting of RCTs as 
measured by adequate or inadequate reporting of the 25 items on the 2010 Consort checklist. 
Secondary end-points included comparison of quality of reporting by year from 2011 to 2016, 
correlation of reporting with Impact Factor and number of Randomized Participants, as well as a 
sub-group analysis which compared the quality of reporting of 5 CONSORT items (7a, 8a, 8b, 9, 
16), which are considered to be “key methodological factors”, between two time periods (May 
2011-2013 & 2014-May 2016). 
RESULTS: The search identified 55 eligible articles for analysis. Overall compliance was 63,10%. 
Only 15 out of the 55 (27,3%) articles reported at least 75% of the checklist items, while only 14 
out of the 37 items were reported in 75% or more of the articles. No significant improvement in 
the reporting quality of the articles over time was found. Correlations were found to be 
significant but after adjusted for co-factors the significance was lost, whereas a statistical 
significant difference (p<0,05) was found in the reporting of “5 key methodological factors” 
during the two time periods. 
Conclusions: Completeness of reporting in RCTs focusing on patients with MM still remains 
unsatisfactory and no clear evidence of improvement over time was found in our study. These 
results suggest that further actions should be taken by authors, reviewers, and editors, since 
inadequate reporting makes the interpretation of RCTs difficult if not impossible. 
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evaluating new treatment strategies [1, 4]. The unique capability of randomized controlled trials to 
reduce bias depends on investigators being able to implement their principal bias reducing technique—
randomization [2].  
The randomized controlled trial is one of the simplest but most powerful tools of research. In 
essence, the randomized controlled trial is a study in which people are allocated at random to receive 
one of several clinical interventions [3, 6]. Random assignment has been successfully used for over 55 
years and is now the preferred method for determining the merits of interventions [5, 10].  
 
If complete matching could be achieved, the testing of therapies would be easier. However, the 
marked variability of human responses to both diseases and treatments and the realities of observer 
error and bias make proper matching impossible to attain. For this reason randomization is recognized 
as the best available technique of approximating the equality of patient groups being compared [14]. 
Randomization is a procedure that allows for chance allocation of trial participants to the treatment 
groups. The procedure in principle ensures that treatment groups are balanced in terms of baseline 
characteristics and thus any significant differences between groups in the outcome event can be 
attributed to the intervention and not to some other unidentified factor, thereby providing the basis for 
crude between-group comparison of treatment effect [7].  
According to Hill who stressed the objectivity of randomization: “having used a random allocation, 
the sternest critic is unable to say when we eventually dash into print that quite probably the groups were 
differentially biased through our predilections or through our stupidity”. [15, 16] 
The successful implementation of this all-important procedure, as was observed by previous authors 
[2] depends on two main procedures:  
1) generation of an unpredictable random allocation sequence and  
2) concealment of that sequence until assignment occurs. [3,7] 
 
 
Evidence Of Bias 
Though randomized controlled trials are widely agreed to yield the most reliable scientific 
information, careless or inappropriate analysis may lead to misleading conclusions [19]. An 
overwhelming amount of information available in biomedical journals during the past 50 years has 
created problems in a variety of areas, such as publication or selection bias [24, 25] 
 The validity of an RCT depends on the correct performance of a large number of essential steps. 
Unless all these steps are accurately accounted for and described, critical clinicians cannot know what 
actually took place, cannot judge whether the conclusions drawn by the authors are justified, and cannot 
judge whether their patients are likely to be helped or harmed by the intervention [17]. Reports of RCTs 
should provide readers with adequate information about what went on in the design, execution, 
analysis, and interpretation of the trial. Such reports will help readers judge the validity of the trial [18]. 
Evidence produced repeatedly over the last 30 years indicates a wide chasm between what a trial 
should report and what is actually published in the literature. [21] 
R A. Fisher[11] firstly developed randomization as a basic principle of experimental design in 
the 1920s, and used the technique predominantly in agricultural research. The successful 
adaptation of randomized controlled trials to health care took place in the late 1940s, largely 
because of the advocacy and developmental work of Sir Austin Bradford Hill [16]. His efforts 
culminated in the first experimental [13] and published [9] use of random numbers to allocate trial 
participants. The Medical Research Council trials on streptomycin for pulmonary tuberculosis are 
rightly regarded as a landmark that ushered in a new era of medicine [2, 9]. Soon after, 
randomization emerged as a crucial technique in securing unbiased comparison groups and the 
methodology of the randomized controlled trial has been increasingly accepted while the number 
of randomized controlled trials reported has grown exponentially. [2, 3]  
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Even from the 1980s Fr. Mosteller & Colleagues [22] in a survey of controlled trials in cancer noticed 
deficiencies in current reporting standards of that period and stressed out that published articles do not 
give readers essential information needed to judge a trial's methodological strengths. Unless such 
details are reported, readers cannot adequately assess the confidence a trial's results deserve [22]. The 
features, Mosteller & Colleagues,  looked for in their review were reports of 1) how randomization was 
carried out, 2) P-values, that is, explaining the statistics used, 3) survival curves, 4) blindness in the trial, 
5) power and sample size, and 6) informed consent. The reason for selecting the above mentioned 
features is that beyond their importance, these features have the advantage of ease of recognition in a 
report or an explanation. Finally they argued that: “Certain features could not have been implemented in 
some of these studies, in others they clearly could have been. However, as readers, we were not always in a 
position to evaluate when a feature could or could not have been implemented in each comparison” [22]. 
Or to put it differently, in interpreting trial results, the reader has only the published paper on which to 
rely on [14].   
 In the same article Mosteller et al [22] points out that only 3 out of the 19 clinical trials in the 
Myeloma and Leukemia group that they reviewed reported the method of randomization, he continues 
saying that “especially if the method is not reported, the skeptic must be allowed doubts about the 
effectiveness of the method used. Not only must the randomization be well done, but it is best if it can be 
checked on later, should questions arise, as they frequently do”. In conclusion Mosteller et al 
recommended that in order encourage authors to include the appropriate descriptions, the editor 
should provide a checklist of items expected to be published in a report on a clinical trial [22]. 
In 1983, Chalmers and colleagues [26] found that trials in which the allocation schedule had been 
inadequately concealed yielded larger estimates of treatment effects than trials in which allocation had 
been adequately concealed [20]. Later Schulz and colleagues have shown empirically that in comparison 
with trials in which authors reported adequately concealed treatment allocation, trials in which 
concealment was either inadequate or unclear (i.e. did not report or incompletely reported a 
concealment approach) yielded larger estimates of treatment effects (P<.001), while odds ratios were 
exaggerated by 41% for inadequately concealed trials and by 30% for unclearly concealed trials [20]. 
One possible interpretation is that some trials with inadequate reporting of allocation concealment 
actually had faulty randomization, and faulty randomization allowed the introduction of bias [21]. 
In separate reviews of medical journals concerning the adequacy of randomization procedures in 
trials, studies [2] & [25] respectively found 129/206 (63%) and 79/232 (34%) of authors did not 
specify the method used to generate an allocation sequence, despite the presence of a “Consolidated 
Standard of Reporting Trials” (CONSORT) [10] statement that stipulated that authors should make clear 
how randomization was conducted. The result of these reviews also shows that non-random methods 
such as using case record number, date of birth and date of presentation are still being confused and 
presented as a random method by some researchers. Therefore we can reach the conclusion that non-
reporting of the allocation technique in some controlled clinical studies could be because the methods 
used by the authors of such studies were short of a true random process [7] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:04:59 EET - 137.108.70.7
4 | P a g e  
 
CONSORT 
In response to overwhelming evidence and consequences of poor–quality reporting of RCTs, the 
Consolidated Standards of Reporting Trials (CONSORT) statement came about because of the need to 
provide readers with enough valid and meaningful information concerning the design, conduct, and 
analysis of RCTs [21]. 
 
The original Consort statement has been revised twice so far. The first revision was in 2001 [10, 27, 
28] and thereafter updated to its current version in 2010 [29]. The 2010 CONSORT statement comprises 
of a 25 items’ checklist along with a flow diagram documenting the flow of participants through RCTs. It 
provides guidance for reporting all randomized controlled trials, but focuses on the most common 
design type, which are the “individually randomized, two group, parallel trials”[29].  Since its 
publication in 1996 the consort statement has been widely supported, it has been translated into 13 
languages [30] while there are currently 585 biomedical journals worldwide that endorse the CONSORT 
statement [31].   
The CONSORT statement has evolved as evidence based approach to improve the quality of reports 
of RCTs, enabling readers to understand their conducts and to gauge the validity of their results [32]. 
Diligent adherence by authors to the checklist items facilitates clarity, completeness, and transparency 
of reporting [29]. Providing reporting quality could be used as a proxy measure for methodological 
quality [33]. This could be justified if the assumption were correct that faulty reporting reflects faulty 
methods [34] However, even if the quality of reporting does not reflect absolutely the quality of the 
research and the adequacy of the methods, it is well accepted that unclear and inaccurate reporting 
reflects faulty methods, while a well-conducted but badly reported trial will be misclassified [20, 8, 34]. 
It is justified to say that the thorough use of the CONSORT guidelines affects trials’ quality, since it can 
indirectly affect their design and conduct. Transparent reporting can reveal deficiencies in research if 
they exist. Thus, investigators who conduct inadequate trials, but who must transparently report, 
should not be able to pass through the publication process without revelation of their trial's 
inadequacies. That emerging reality should provide impetus to improved trial design and conduct in the 
future. Taking into account all of the above, the CONSORT statement should not be used as a quality 
appraisal tool but rather as a guide for reporting of RCTs [33]. 
As such, while the CONSORT Statement is widely endorsed, there is huge variation in terms of how 
CONSORT policies are implemented [35]. A number of publications have studied the quality of reports 
of RCTs in subspecialties of medicine [4, 5, 32, 36, 37, 38, 39, 40, 45] in the recent years. Among these 
subspecialties the Hematology field and Multiple Myeloma disorder in particular hasn’t escaped without 
judgment of the reporting quality of its published clinical trials. 
    
The first step was made when JAMA published in December 1994 the Standards of Reporting 
Trials (SORT) statement. The authors of the SORT statement defined structured reporting as 
"providing sufficiently detailed information about the design, conduct and analysis of the trial for 
the reader to have confidence that the report is an accurate reflection of what occurred during the 
various stages of the trial" and proposed 32 items for inclusion in a checklist to be used when 
preparing a report of an RCT. [18] 
Independently, approximately 5 months later (March 14 to 16, 1994), another group, the 
“Asilomar Working Group on Recommendations for Reporting of Clinical Trials in the Biomedical 
Literature”, met to discuss similar challenges facing the reporting of clinical trials. Their proposal 
consisted of a checklist of items that should be included when reporting a clinical trial, along with a 
suggestion that editors add it to the “Instructions for Authors” section[21]. A subsequent Editorial 
[17] urged both groups to meet and decide which recommendations from each group's proposal 
should be retained. This meeting resulted in the Consolidated Standards of Reporting Trials 
(CONSORT) statement of 1996, which consists of a checklist of 21 items along with a flow diagram 
that pertain mainly to the methods, results and discussion of an RCT report and identify key pieces of 
information necessary to evaluate the internal and external validity of the report [21]. 
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In 2001 a review, which critically appraised therapeutic innovations tested in RCTs from 1966 to 
1998 for Multiple Myeloma patients, was published. That particular review assessed RCTs in terms of 
quality dimensions of design, conduct, analysis and reporting [4]. However, no other study to our 
knowledge has assessed the quality of reporting of RCTs, focusing on patients with MM, using the items 
of the revised 2010 CONSORT statement. 
In the present study, we analyzed the quality of reporting of RCTs involving treatments of patients 
with Multiple Myeloma, using the items of the revised 2010 COSORT statement [29]. The period covered 
by this report is the last 5 years (from May 2011 to May 2016). 
 
 
Multiple Myeloma 
Multiple myeloma (MM) is a neoplastic plasma cell disorder. Plasma cell neoplasms have 
proven challenging to classify in a biologically correct and clinically useful way [43]. According 
to WHO classification of 2008 other clinical entities that fall into the same plasma cell 
neoplasms category as MM are: Monoclonal gammopathy of undetermined significance (MGUS), 
plasma cell myeloma (asymptomatic/smouldering myeloma, non-secretory myeloma, plasma 
cell leukemia), plasmatocytoma, Immunoglobulin deposition diseases and osteosclerotic 
myeloma (POEMS syndrome)[12]. 
MM is a disorder characterized by clonal proliferation of malignant plasma cells in the bone 
marrow, and usually monoclonal protein in the blood and/or urine. It is associated with end-
organ damage consisting of the CRAB criteria (anaemia, renal insufficiency, bone lesions and/or 
hypercalcaemia). It is the second most frequent haematological neoplastic disease after non-
Hodgkin lymphoma and comprises 1% of all cancers and 10% of haematological malignancies. 
It primarily affects older individuals; the median age at the time of diagnosis is 70 years, and 
two-thirds of MM patients are over 65 years of age when first diagnosed [41, 42]. 
There are a number of strategies for management of patients with multiple myeloma, and 
decisions are based on a variety of factors including patient factors such as age, end-organ 
function, and cytogenetics. At this time induction therapy is given to most patients with active 
disease and may include corticosteroids, cytotoxic agents, immunomodulating agents, 
proteasome inhibitors, or a combination of these agents [44]. Patients according to their age 
and co-morbidities are broadly subdivided into two categories, those who are able to undergo 
stem cell transplantation and those who are ineligible for transplantation. Patients who are 
eligible for high-dose chemotherapy followed by stem cell transplantation often proceed to 
autologous stem cell transplantation (ASCT) following induction therapy, while patients who 
are not considered “fit” for transplantation are treated with treatment strategies utilizing a 
variety of anti-myeloma drugs. Over the last decade, along with the conventional chemotherapy 
(melphalan etc), numerous drug therapies have emerged for the treatment of multiple myeloma 
including immunomodulating agents (namely thalidomide, lenalidomide, and pomalidomide), 
proteasome inhibitors (namely bortezomib and carfilzomib) and monoclonal antibodies, such 
as daratumumab (anti-CD38). Although a hope was expressed in the early years of their 
discovery that with the new agents the need for ASCT for younger and fit patients would be 
diminished, the usefulness of ASCT remains still today unquestionable according to recently 
published RCTs[47].  Nonetheless these agents have transformed the treatment of multiple 
myeloma and the role of high-dose chemotherapy followed by stem cell transplantation in the 
treatment of the disease [44].  
Finally it is not wrong to say that MM is a complicated clinical entity which requires 
sophisticated multimodal interventions and treatment schedules. Almost all major therapeutic 
advances and treatment strategies for this disease have occurred as a result of RCTs. 
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 Search Stretegies 
Literature for this review was systematically identified by screening the electronic database 
“PubMed” for reports on RCTs involving patients with MM published the last 5 years (with starting 
point the date when we made our search, “between May 2011 and May 2016”). The search criterion we 
used was “Multiple Myeloma” and the restrictive filters we used were: “Clinical Trial” for the article 
type, “English” for language, “Human” for species and “5 years” for publication dates.  
 
Study Identification 
References were screened by one researcher (NP) for eligibility in the study. Trials were eligible if 
they had randomly assigned participants to at least two treatment arms and included patients with MM 
comprising also of clinical entities related to multiple myeloma that fall into the same category of 
“plasma cell neoplasms” (MGUS, plasma cell myeloma, plasmatocytoma, Immunoglobulin deposition 
diseases and osteosclerotic myeloma). We looked for the terms “random”, “randomized” and 
“randomization” as an indicator of the way/method by which participants were assigned to treatment 
groups. To be included in the study, RCTs must have randomized human subjects into two or more 
“therapeutic” interventions, while RCTs evaluating diagnostic strategies were excluded. Reports of 
trials regarding treating symptoms of MM or coping with side effects were excluded. Also all 
observational studies, reviews, small pilot studies, meta-analysis and pooled analysis of RCTS, as well as 
short communications, editorials,  non-patient RCTs and any article with information resulting from a 
previous conducted trial (post-hoc analysis, sub-group analysis, sub-studies) were excluded. 
 
Reporting assessment tool 
As assessment tool for reporting quality we used the revised CONSORT 2010 checklist which can be 
found through the CONSORT- website (http://www.consort-statement.org). This checklist comprises of 
a 25-item checklist with sub-items (37 items in total), that provide guidance in reporting randomized 
controlled trials. As guidelines we used “the CONSORT explanation and elaboration document” 
(available at the CONSORT web page) [46]. Although all items in the CONSORT checklist are considered 
important as to improve the quality of reporting of RCTs, some are more subjective than others [40]. Α 
variety of other studies have identified a number of methodological factors as necessary items that can 
judge the internal validity of RCTs [4, 20, 26, 40, 48, 49]. After identifying the most common items 
reported by these studies, emphasis was placed in examining the 5 mostly cited “key methodological 
factors” that are also included in the 2010 CONSORT statement. These items, which can and should be 
implemented in each and every complete randomized trial, have been shown to bias outcomes, and 
included details about: sequence generation, allocation concealment, randomization implementing 
method, justification of sample size, and whether the analysis was done by original assigned groups 
(intention to treat analysis) along with the number of participants for each group included in each 
analysis {CONSORT 2010 items (7a, 8a, 8b, 9, 16)}.  
 
Evaluation & analysis of outcomes 
The primary outcome of this study is the evaluation of the completeness of reporting of RCTs as 
measured by adequate or inadequate reporting of the 25 items on the 2010 Consort checklist. The 
procedures followed to achieve this goal are outlined bellow: 1) The items in the checklist were 
investigated in terms of whether they were reported or not. No assessment was made on the quality of 
what was reported or if they were actually carried out during the trial. 2) Response alternatives to each 
item in the checklist originally were: yes, no, unclear, and not applicable. Not-applicable responses were 
coded as missing data. However during the course of this study we noticed that what constitutes 
’complete’ reporting for each checklist item appeared to be variable between evaluations, depending on 
author’s interpretation. A review by Turner et al on the completeness of reporting of RCTs 
recommended that future evaluations assess the completeness of reporting of each checklist item in a 
dichotomous fashion (i.e. ’complete’ versus ’incomplete’) and moreover generally suggested to trial 
authors that items are only ’complete’ when adhered to in their entirety.  After all it is the intention of 
the CONSORT group that all concepts contained within an individual checklist item to be reported in 
METHODS 
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order to be considered adequately (or completely) reported [35]. For the reasons mentioned above we 
revised our methods and thus when evaluations used more than two categories to judge adherence to a 
given checklist item, we collapsed them to create a dichotomous value between adequately or 
inadequately reported RCTs, which is translated to the reporting or non-reporting of a checklist item. 
For instance, when an item was judged as ’partially’ reported, it was considered ’inadequate’ i.e. not-
reported. So each applicable item in the CONSORT checklist entails a YES or NO response option. 
An item was graded a score of “one”= YES, if there was a statement describing the item and clear 
description of the method used was required to define the adequacy of the assessed component. If no 
description of the item was included, the item would be graded a score of “zero”= NO. Omission or 
unclear information were equated to inadequate reporting quality and were graded a score of “zero”. 
When an item was non-applicable to a certain RCT it was considered as missing data and was not 
accounted for in the calculation of the results (it was omitted both from the numerator and the 
denominator). 3) It didn’t matter whether an item was reported in a different section of the trial, “it is 
not the intention of the CONSORT group to standardize the structure of reporting, authors should 
simply address checklist items somewhere in the article, with ample detail and lucidity [29]”, with an 
exception for the items that were reported only in the abstract and not the full paper. If a checklist item 
that is supposed to be reported in the main article but was found only in the abstract it received a 
negative response (e.g. item 23 “registration number and name of trial registry was frequently reported 
in the abstract but not in the main article). 4) For items which in a first glance received a negative 
response, but in the article were clearly referred to in the “appendix” or the “supplementary data” for 
more information, then we would examine the reference and if the item was adequately reported it 
could entail a positive response. An exception to this rule was made for the item 8a-“method used to 
generate the random allocation sequence”, where the CONSORT Explanation and Elaboration Document 
specifically states that “it is important that information on the process of randomization is included in 
the body of the main article and not as a separate supplementary file; where it can be missed by the 
reader” [46].  
For secondary outcomes in addition to the primary end point of evaluating the overall completeness 
of reporting of RCTs, 1) we attempted to detect if there was an improvement of compliance over time. 
To test for reporting differences over time, studies were grouped by year starting from 2011 and 
reaching to 2016 (six groups: 2011-2012-2013-2014-2016). 2) We also separated the checklists’ items 
into four groups according to the sections of the published article: i) Title/Abstract & Introduction, ii) 
Methods, iii) Results, vi) Discussion & Other information and then we calculated the compliance of the 
checklist items in each of the 4 groups. 3) We collected information on the number of patients that were 
randomized in each trial and examined possible association with reporting. 4) Finally we examined if 
the impact factor of the journal where the trial was published was associated with the number of 
reported items. 5) A subgroup analysis of completeness of reporting for the five key methodological 
factors described earlier was also carried over.  
Statistical Analysis 
We calculated the various frequencies of compliance as a percentage after adjusting for checklist 
items which were not applicable in certain RCTs. So the general formula we used for compliance is: 
 
Compliance (%) = 
𝑹𝒆𝒑𝒐𝒓𝒕𝒆𝒅 𝒊𝒕𝒆𝒎𝒔(𝒀𝑬𝑺)
𝑨𝒑𝒑𝒍𝒊𝒄𝒂𝒃𝒍𝒆 𝑰𝒕𝒆𝒎𝒔
*100% 
 
Were, applicable items = total items - non applicable items 
Were, total items = Reported (YES + NO) + non_applicable items. 
So, applicable items = Reported (YES + NO) 
 
So for example the frequency of compliance for the 1st RCT is: 
Freq(1stRCT)% = 
𝒀𝑬𝑺 in  the  1st  RCT
total −non  applicable  items
*100= 
𝟐𝟔
𝟑𝟕−𝟑
*100= 76,4% 
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1) We calculated the overall number of checklists items reported and estimated overall compliance 
(as a proportion). 2) The number and proportion of checklist items reported in each trial, as well as the 
number and proportion of checklist items reported in each trial by time period was calculated. We then 
calculated the number and proportion of articles, overall and by time period, which had addressed at 
least the 75% of the checklists’ items (i.e. articles’ (>75%) compliance). The 75% cut-off point of 
compliance has been used previously as an adequate measure of compliance in various studies [32, 45].  
We used the Pearsons’ chi-squared statistic to compare the 75% compliance of trials between the 6 time 
periods.  3) Moreover the number and proportion of each CONSORT items being reported by articles 
was estimated for the whole time period (i.e. how many times each checklist item was reported as an 
absolute number and proportion). Also the proportion of checklists items being reported by year was 
reported. We then calculated the number and proportion of checklist items, which were reported in at 
least 75% of the trials (i.e. checklist (>75%) compliance), overall and by year. We used Pearsons’ chi-
squared statistic to examine whether the (>75%) compliance of reported items improved over time. 4) 
We calculated the number and proportion of trials reporting each checklist item by group (i.e. how 
many times are checklist items reported in their group. 4 groups i) Title & Abstract, ii) Introduction, iii) 
Methods, iv) Results, v) Discussion & Other information}. We then calculated the number and 
proportion of “checklists’ 75% compliance” in each group (i.e how many items with (>75%)compliance 
in the articles are found in each group). 5) Pearson’s correlation analysis was performed to examine the 
relationship of completeness of reporting i) with the number of the participants randomized in each 
trial & ii) with the impact factor of the journal. 6) We calculated the number and proportion of the “5 
key methodological factors” reported in each trial and then estimated the compliance overall and by 
time period. We compared compliance between two time periods (May 2001-2013) & (2014- May 
2016) using Hotteling’s T-test. The impact factor of the journals was retrieved from the Thomson 
Reuters Citation Reports web site. Evaluation of the CONSORT items in the 55 RCTs and calculation of 
the corresponding frequencies was done with the use of Microsoft Excel 2007. All statistical analyses 
were made on the IBM SPSS v.22 package. The cutoff point for statistical significance was set at the two-
sided 0.05 level. Data extraction and article assessment was made by one author (NP). 
 
 
 
 
The screening process for acquiring the eligible RCTs was executed in four steps. The first search 
meeting of the electronic database “Pubmed” was established on 1st May 2016 and it procured 539 
related articles according to the search criteria mentioned above. From the 539 articles 103 were 
excluded as irrelevant by screening the title alone (observational/ non-interventional studies, non-
theurapeutic intervention, non-randomized trials, post-hoc/ sub-group analysis or trials not relevant 
with multiple myeloma). The remaining 436 articles were reviewed by abstract and thus excluding 299 
more non-eligible articles. Finally the last 137 articles after being reviewed by full text 82 were found 
irrelevant, leaving 55 eligible articles to be included in the study. A list of the 55 RCTs that included a 
total of 21.761 patients, as well as the flowchart (figure_1) of the screening process can be retrieved in 
the Supplementary material (APPENDIX). 
 
 
 
 
 
RESULTS 
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Overall compliance, compliance per article, (>75%)compliance per article & by time period 
 
Table_1 
Year Journal  
2016(May) 7 Blood 14 
2015 11 N Engl. J Med. 9 
2014 6 Lancet Oncol. 7 
2013 11 J Clin Oncol 4 
2012 14 Haematologica 3 
2011(May) 6 Others 18 
Total 55 Total 55 
 
The RCTs that covered more than 75% of the CONSORT items were 15 (27.20%). The average 
compliance by time period as well as the absolute number and proportion of RCTs with (>75%) 
compliance by time period are presented on the table bellow (table 2).  
Table 2 
Year Total RCTs 
per year 
Number of RCTs with 
>75% compliance 
Proportion of RCTs with 
>75% compliance (%) 
Compliance per year 
(%) 
2016  7 3 42,85 67,67 
2015  11 4 36,65 67,90 
2014  6 3 50 71,43 
2013  11 2 18,18 61,71 
2012  14 1 7,14 57,93 
2011 6 2 33,3 54,97 
Total 55 15 27,2 63,10 
 
As we can observe from the diagram bellow (diagram_1), there seems to be a tendency towards better 
75% compliance of the articles over time, (i.e. there seems to be more articles with >75% compliance 
over time) . We tested this hypothesis using a chi-squared test for a two by six (2*6) table. However, even 
if the percentages of RCTs that have 75% compliance seems to grow over time, this difference is non-
significant for a possibility of error of 5%, since p = 0,27 > 0,05. (More information on the 2x6 table and 
the Pearson Chi-Square test can be found in the APPENDIX). 
Out of the total 55 eligible articles, 7 were 
published in 2016 (May), 11 in 2015, 6 in 2014, 11 
in 2013, 14 in 2012 and 6 in 2011(May), all in the 
last 5 years (May 2011 – May 2016)from the time 
we began our search. The articles were published in 
18 different medical journals with mean Impact 
Factor: “20.2”, min: “2.06” and max: “55.87”. The 
overall CONSORT compliance score was 63,10%.  
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Absolute numbers and proportional compliance of items reported in each trial, along with: numbers of 
non-applicable CONSORT items in each trial, the number of patients that were randomized in each trial 
and the Journal where each trial was published, with the corresponding Impact Factor are presented on 
table_3 bellow. 
Table 3 
No. 
RCTs 
Year Items 
Reported 
non-applicable 
items 
Compliance (%) JOURNAL 
 
Impact Factor Randomized 
Participants 
1 2016 26 3 76,47 N Engl J Med. 55.873 722 
2 2016 17 6 54,84 Blood 10.452 668 
3 2016 26 4 78,79 Lancet 45.217 124 
4 2016 21 2 60,00 Blood 10.452 662 
5 2016 29 3 85,29 Lancet Oncol 24.69 929 
6 2016 19 3 55,88 Ann Hematol 2.634 82 
7 2016 19 6 61,29 Blood 10.452 233 
 Total 131 27 67,67   3.420 
8 2015 30 4 90,91 Lancet Oncol 24.69 256 
9 2015 19 3 55,88 Blood 10.452 306 
10 2015 17 8 58,62 Haematologica -  100 
11 2015 26 4 78,79 J Clin Oncol 18.428 502 
12 2015 24 5 75,00 N Engl J Med. 55.873 646 
13 2015 22 4 66,67 Br J Haematol 4.711 95 
14 2015 12 3 35,29 Blood 10.452 40 
15 2015 23 4 69,70 Biomed Res Int -  209 
16 2015 23 13 95,83 BMJ Open 2.063   
17 2015 21 5 65,63 N Engl J Med. 55.873 792 
18 2015 22 2 62,86 Am J Hematol 3.798 281 
 Total 239 55 67,90   3.227 
19 2014 28 1 77,78 Lancet Oncol 24.69 768 
20 2014 23 5 71,88 N Engl J Med. 55.873 524 
21 2014 26 5 81,25 N Engl J Med. 55.873 1623 
22 2014 30 4 90,91 Lancet Oncol 24.69 174 
23 2014 13 6 41,94 Blood 10.452 106 
24 2014 20 5 62,50 Blood 10.452 221 
Diagram_1 
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 Total 140 26 71,43   3.416 
25 2013 24 5 77,42 Lancet Oncol 24.69 637 
26 2013 29 4 87,88 Lancet Oncol 24.69 455 
27 2013 18 4 54,55 N Engl J Med. 55.873 125 
28 2013 18 5 56,25 Biol Blood Mar 3.404 50 
29 2013 16 4 48,48 Blood 10.452 370 
30 2013 22 5 68,75 Blood 10.452 455 
31 2013 21 5 65,63 Blood 10.452 332 
32 2013 18 8 62,07 J Clin Oncol 18.428 98 
34 2013 9 5 28,13 Cancer Immunol  3.941 48 
35 2013 21 5 65,63 Leukemia 10.431 68 
36 2013 20 6 64,52 Cancer -  102 
 Total 216 56 61,71   2.740 
33 2012 11 14 47,83 BMC Cancer 3.362 302 
37 2012 22 4 66,67 J Clin Oncol 18.428 827 
38 2012 16 6 51,61 Blood 10.452 390 
39 2012 21 4 63,64 Am J Hematol 3.798 1213 
40 2012 21 4 63,64 J Clin Oncol 18.428 269 
41 2012 18 0 48,65 N Engl J Med. 55.873 460 
42 2012 22 2 62,86 N Engl J Med. 55.873 459 
43 2012 23 0 62,16 N Engl J Med. 55.873 614 
44 2012 21 3 61,76 Blood 10.452 158 
45 2012 24 5 75,00 Eur J Haematol. 2.066 131 
46 2012 16 6 51,61 Haematologica -  499 
47 2012 17 5 53,13 Haematologica -  1114 
48 2012 18 5 56,25 Eur J Haematol. 2.066 400 
50 2012 13 6 41,94 Cancer -  60 
 Total 263 64 57,93   6.896 
49 2011 10 6 32,26 Immunotherapy 2.44 682 
51 2011 19 6 61,29 Blood 10.452 199 
52 2011 14 4 42,42 Ann Hematol 2.634 91 
53 2011 26 6 83,87 Blood 10.452 856 
54 2011 9 3 26,47 Br J Haematol 4.711 12 
55 2011 27 6 87,10 Lancet Oncol 24.69 222 
 Total 105 31 54,97   2.062 
Sum  1022 259 63,10  Mean:20.2 21.761 
 
 
 
Compliance per item & (>75%) compliance of items by time period 
 
The absolute numbers and proportions of items being reported by the articles overall as well as the 
proportions per year by year can be found on table 5. 
Table 5 
 Reported 
Items 
Compliance 
(%) 
2016 2015 2014 2013 2012 2011 
Abstract/title         
1a 30 54,5 28,57 54,55 66,67 63,64 64,29 33,33 
1b 11 20 28,57 18,18 66,67 18,18 0 16,67 
Introduction       64,29  
2a 49 89,1 100 100 100 90,91 100 100 
2b 52 94,5 85,71 100 83,33 45,45 35,71 100 
Methods         
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3a 27 49,3 57,14 45,45 83,33 100 40 50 
3b 11 73,3 100 100 0 72,73 92,86 40 
4a 46 83,6 85,71 90,91 100 45,45 35,71  50 
4b 29 52,7 57,14 54,55 83,33 90,91 100 66,67 
5 52 94,5 100 100 83,33 72,73 85,71 83,33 
6a 45 81,8 85,71 90,91 100  50 50 
6b 1 33,3   0 81,82 71,43  
7a 42 76,4 85,71 72,73 100 100 50 50 
7b 19 63,3 80 62,50 33,33 18,18 21,43  
8a 17 30,9 42,86 45,45 33,33 54,55 50 33,33 
8b 30 54,5 71,43 63,64 50 18,18 14,29 33,33 
9 16 29.1 42,86 27,27 66,67 18,18 0 33,33 
10 10 18,2 28,57 27,27 16,67 20 16,67 33,33 
11a 7 30,4 0 42,86 100 20 0 50 
11b 5 22,7 0 33,33 100 81,82 92,86 50 
12a 46 83,6 85,71 81,82 100 71,43 84,62 50 
12b 37 78,7 57,14 100 100 81,82 84,62 50 
Results         
13a 44 83 85,71 90 66,67 71,73 61,54 83,33 
13b 37 69,8 71,43 70 83,33 90,91 85,71 66,67 
14a 41 74,5 28,57 90,91 83,33 100 100 33,33 
14b 11 91,7 100  50 100 100 100 
15 52 98,1 100 100 100 63,64 69,23 83,33 
16 34 64,2 57,14 70 50 81,82 92,31 66,67 
17a 44 83 85,71 80 66,67 45,45 38,46 83,33 
17b 31 58,5 85,71 80 50 40 83,33 66,67 
18 32 74,4 85,71 62,65 80 81,82 84,62 83,33 
19 48 90,6 100 90 100 54,55 14,29 100 
Discussion         
20 21 38,2 57,14 45,45 50 54,55 28,57 16,67 
21 29 52,7 57,14 72,73 83,33 100 100 33,33 
22 53 98,1 100 100 100 45,45 14,29 83,33 
Other 
Information 
        
23 18 32,7 57,14 27,27 33,33 9,09 21,43 33,33 
25 9 16,4 14,29 18,18 33,33 54,55 57,14 0 
25 34 61,8 71,43 81,82 66,67   33,33 
Total 1120 63,10       
 
The whole time period (May 2011- May 2016) 14 items (62,2%) were reported in more than 75% of 
the 55 articles {checklists’ (>75%) compliance}. These checklist items were: 2a, 2b, 4a, 5, 6a, 7a, 12a, 
12b, 13a, 14b, 15, 17b, 19 and 22.  
The number and percentages of CONSORT items reported by more than 75% of the articles by time 
period are presented in table 6, while diagram 2 shows the number of CONSORT items with (>75%) 
compliance over time. 
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Table 6 
Year Number of items with 
>75% compliance 
Proportion of items with 
>75% compliance (%) 
2016 17 47,22 
2015 16 45,71 
2014 19 51,35 
2013 14 38,89 
2012 14 37,84 
2011 10 29,41 
 
 
 
 
 
 
 
 
 
Although the number of CONSORT items which are reported in articles each year seem to increase 
slightly (i.e. more and more items seem to achieve (>75%) reporting from articles every year), the 
difference in the increase is not statistical significant (p= 0,49 > 0,05). More detailed information about 
the Pearson chi-squared test of the 2x6 table can be found in the appendix) 
 
 
Number and proportion of trials reporting each checklist item by group 
 
As we mentioned before a total of 14 CONSORT items were reported in the 55 articles. The numbers 
and proportions of items with (>75%) compliance group, as well as the average compliance per group 
are presented on the table_7 bellow. 
 
Table 7 
Group Number of items with 
(>75%) compliance 
Percentage of items with 
(>75%) compliance (%) 
Compliance per 
group (%) 
Title/abstract & Introduction 2 50 64,5 
Methods 6 35,3 56,3 
Results 5 50 78,8 
Discussion & Other 
Information 
1 16,7 50 
 
 
Association with Impact Factor & Number of  Randomized participants 
 
i) As far the association of completeness of reporting with the Impact Factor of the journal where the 
article was published is concerned, we found out that the impact factor does correlate positively with 
the reporting of checklists’ items. More specifically we found a positive R= 0.308 with possibility for 
error less than 5%, (p=0,032< 0, 5). However R-squared= 0,095, which means that only 9, 5% of the 
variation of the reporting can be accounted for by the Impact Factor. Even so, we have proven that 
journals with higher Impact Factor, affect positively reporting.  
ii) Moreover we revealed a positive association between the number of the randomized participants 
and the completeness of reporting. In this case we found a positive R= 0,320 with a possibility for error 
less than 5% (p=0,018) and R-squared=0,102. 
As a next step we tried to identify how well is the “frequency of reporting” described by the “Impact 
Factor” together with the “number of the randomized participants”. To examine this correlation we 
created a linear regression line which included these two variables. However we found out that when 
 
Diagram 2 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:04:59 EET - 137.108.70.7
14 | P a g e  
 
we enter these two variables in the regression equation together, their coefficients cannot account for 
the reporting frequency in a statistical important standard. 
-> “reporting quality”= 0,012*Randomized_participants + 0,223*Impact_Factor, were p=0,08 & 
p=0,07 for the Randomized_participants & the Impact_Factor accordingly. 
 We noticed next that when we examine the correlation of the Impact Factor with the reporting 
quality, adjusted for the number of participants, as well as the correlation of the number of participants 
with the reporting quality, adjusted for the Impact Factor, these associations ceased to be statistically 
important.  
(Additional information about the Pearson’s bivariate correlation, the partial correlation and the 
regression line we employed can be found in the Appendix). 
 
 
Compliance of “5 key methodological factors” 
 
The overall compliance of the “5 key methodological factors” is 50,91%, while only 7 out of the 55 
articles (12,7%) report completely these factors. On the table below the proportion of reporting of each 
factor by year, as well as the average compliance per year is presented. 
 
Table_8  
(%) 2016 2015 2014 2013 2012 2011 Total 
7a 85,71 72,73 100,00 81,82 71,43 50,00 76,4 
8a 42,86 45,45 33,33 18,18 21,43 33,33 30,9 
8b 71,43 63,64 50,00 54,55 50,00 33,33 54,5 
9 42,86 27,27 66,67 18,18 14,29 33,33 29,1 
16 57,14 70,00 50,00 63,64 69,23 66,67 64,2 
Total 60 55,56 60 47,27 44,43 43,43 50,91 
 
We wondered whether the reporting of these “5 key methodological factors” differed over time. For 
this reason we compared two time periods: (2011-2013) & (2014-2016). In order to examine if the two 
time periods differed based on the reporting of these 5 factors combined, we will use Multivariate 
Analysis of Variance (MANOVA). 
From the diagram bellow we notice that the (2014-2016) time period seems to have a better 
reporting quality from the time period (2011-2013), with the 2 lines being in most cases substantially 
far from each other. Moreover we get a mean for time-period (2016-2014) =58, 6%, and a mean for 
time-period (2013-2011)= 45,3%. From the “Multivariate analysis” the Hotteling’s test shows us that a 
statistical significant difference exists for the time period, where p= 0,038 < 0,05,  which means that 
the time periods differ with a possibility of error less than 5% . (Additional details for the above 
analysis can be found in the APPENDIX) 
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The randomized controlled trial, more than any other methodology, can have a powerful and 
immediate impact on patient care. Ideally, the report of such an evaluation needs to convey to the 
reader relevant information concerning the design, conduct, analysis, internal validity and 
generalizability of the trial. For RCTs to ultimately benefit patients, the published report should be of 
the highest possible standard [21], since as Schulz et al concluded in his study [20], without adequate 
reporting, assessing quality becomes impossible.  
 
Analysis 
 However evidence has accumulated to suggest that the reporting of RCTs remains sub-optimal 
[35]. The results of the present study show a similar trend, with essential aspects of RCTs involving 
patients with multiple myeloma being seldom described. Overall compliance with the Consort 
Statement is unsatisfactory displaying a proportion of 63.10% adequate reporting, while for the 
time period May 2011- May 2016  only 15 out of 55 articles, which is less than one-third (27,3%), 
reported at least 75%  of the CONSORT items. At the same time only 14 out of 37 (37,8%) CONSORT 
items were addressed in 75% or more of the studies published the last five years (May 2011 - May 
2016). Some CONSORT items were generally underreported. The least reported item was 24 “where 
the full trial protocol can be accessed, if available”, which is a recent addition to the revised 2010 
CONSORT checklist. A more important finding is that significant methodological information was also 
underreported such as item 8a “method used to generate the random allocation sequence” and item 
9 “mechanism to implement the random allocation sequence describing any steps taken to conceal 
DISCUSION 
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the sequence until interventions were assigned” which were reported only in 30,9% and 29,1% 
respectively. These inadequacies are not to be taken lightly.  Mosteller et al described randomization 
as a principal bias-reducing technique used in clinical trials and continued saying that the method 
used and how well it was followed help determine the credence the reader will have in the reported 
conclusions of a study. He also commented that “When the randomization leaks, the trial's guarantee 
of lack of bias runs down the drain”, thereby published reports of clinical trials should briefly 
describe how the randomization was actually done. Only then can the reader properly evaluate the 
trial [22]. Moreover a number of CONSORT items being non-applicable for some of the RCTs were 
found, especially item 6b “any changes to trial outcomes after the trial commenced, with reasons” 
was not applicable in 94,5% of the articles. Concerning the group distinction according to the 
sections of the article, the part of the “results” tended to be better reported with an average 
compliance of 78,8%, while the least reported section was the “discussion & other information” with 
50% compliance. 
We couldn’t prove that a significant improvement in the reporting quality of the articles over time 
existed. Moreover there was no significant increase to be found in the number of the CONSORT items 
that were reported each year. Although in both cases a trend towards better compliance seemed to 
appear. These findings are similar to that of Djulbegovic et al, who reported that the quality of RCT 
reports in multiple myeloma is modest at best, “clouding the scientific interpretation and immediate 
clinical usefulness of these studies”[4]. Another study assessing CONSORT compliance in myeloid 
malignancies (acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and myelodysplastic 
syndromes (MDS) [32] found a statistical significant improvement over time only in some reporting 
items, while several other important methodological descriptions improved only minimally, which 
comes in terms with the findings of our study, especially when considering the results of our 
subgroup analysis which showed promising reporting over time in the sub-group items examined. A 
more recent study judging the completeness of reporting in RCTs involving patients with multiple 
sclerosis reported more promising results. Although Rikos et al [45] stated that the overall quality of 
reporting in their study was not optimal presenting a low overall compliance rate of 68.2%, quite 
similar to ours (63,10%), they managed to prove that an improvement over time existed, with a 
statistical significant increase (p< 0,05) in the reporting of more than 75% of CONSORT items during 
the three five-year periods (from 2000 to 2015) that they compared. In our sub-group analysis of the 
“5 key methodological factors” we found that the two time periods (2011-2013 & 2014-2046) differed 
in the reporting of these 5 factors overall (p<0,05), with the time period 2013-2016 showing better 
compliance. Apart from that we found a positive association between the Impact Factor where the 
RCT was published and the reporting compliance. A way to interpret this finding is that RCTs 
published in high impact factor journals have a better reporting quality, perhaps because of the 
policies implemented in these journals. However we examined two more correlations which could 
change our view over the subject. We proved that the number of randomized participants was 
associated not only with the reporting quality, but also with the Impact Factor itself. In other words 
bigger and as such more significant studies were better reported (r=0,320 & p=0,018<0,05) and 
because of their significance they tended to be published in more prominent journals (r=0,375 & 
p=0,009<0,05), as these journals are characterized by their Impact Factor. This explains the fact that 
when we examined the correlation of the reporting frequency with the Impact Factor, adjusted for 
the size of the study (i.e. the number of randomized participants) the association ceased to be 
statistically important (p= 0,07 >0,05) 
 
Limitations 
A limitation to our study is that the time period from May 2011 to May 2016 that we used to 
analyze the reporting quality of RCTs is rather small, and may not be enough to identify significant 
differences in reporting quality through time. Also by choosing as a time period the last 5 years from 
the time we first began our search (May 2011- May 2016) we couldn’t as a result include all the trials 
published in 2011 (and of course 2016), and therefore bias could be introduced in our year by year 
comparisons. Moreover, taking into account that the evaluations of the CONSORT items are in a large 
part subjective, another potential limitation to our study is that all the data were extracted and 
analyzed by one reviewer, so there was no way to compensate for any bias that might have occurred 
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from misjudged evaluations. Apart from that, the fact that we included in our study articles published 
only in English could introduce bias, however the number of articles that we retrieved using the 
PubMed search engine written in another language was not significant ( 18 out of 557 or 2,3%). In 
relation to the sub-group analysis, major concerns have been raised whether choosing 5 out of the 37 
CONSORT items to analyze separately would introduce bias. However the selection of these factors 
had been predetermined prior to any statistical analysis, and also their choice was not arbitrary. We 
decided to include these factors in our separate analysis, after reviewing several other studies [4, 20, 
26, 40, 48, 49], which addressed the problem of reporting of RCTs especially, those before 1996 prior 
to the announcement of the CONSORT statement. We concluded to these 5 items after identifying the 
most common factors reported by these studies. Finally we feel that our results could be cautiously 
generalized beyond the Hematology field and the Multiple Myeloma disorder in particular, although 
evaluations about reporting quality in other medical conditions have reached similar conclusions to 
ours. 
 
Conclusion 
CONSORT, came about because of the need to provide readers with enough valid and meaningful 
information concerning the design, conduct, and analysis of RCTs, therefore it is expected that the 
CONSORT statement will ultimately lead to more comprehensive and complete reporting of RCTs 
[21]. However our results summarized indicate that reports of RCTs involving patients with Multiple 
Myeloma do not as yet conform to the CONSORT recommendations, neither have we found strong 
indications of improvement over time. 
Although in proposing structured reporting the main objective was not to pass judgment on the 
quality of the trial itself, but to improve on how it is reported to the reader [18], it is generally 
accepted that the methodological quality of a trial is closely intertwined with the quality of reporting 
[33]. {Note that the CONSORT 2010 Statement does not include recommendations for designing, 
conducting, and analyzing trials. It solely addresses the reporting of what was done and what was found 
[29]}. A principal advantage of such reporting is that all readers will have uniform and standardized 
information to review, unaffected by the writing nuances of authors and the policies of editors. This 
will give readers essential information about what happened during the trial, especially around 
issues affecting a trial's internal validity [18] 
The significance of knowing the status quality of the reporting of RCTs can be easily appreciated 
when we consider the simple fact that physicians, health policy makers and patients have to base 
their decisions on the available published information [4]. Taking into account all of the above, the 
results of our review can only suggest that further actions should be taken by authors, reviewers, and 
editors, since inadequate reporting makes the interpretation of RCTs difficult if not impossible. 
 To conclude I replicate [16] the words of a passage that Hill [15] quoted from an editorial in 
British Medical Journal, which can clearly describe the significance of the issue under discussion: 
 
  
 
 
 
 
 
 
 
 
 
“In treating patients with improved remedies we are, whether we like it or not, 
experimenting on human beings, and a good experiment well reported may be more 
ethical and entail less shirking of duty than a poor one”. 
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 2x6 table and the Pearson Chi-Square test comparing the (>75%) compliance of RCTs, over time. 
TIME * COMPLIANCE_75 Crosstabulation 
Count   
 
COMPLIANCE_75 
Total 
(-) 
75%COMPLIAN
C 
(+) 
75%COMPLIAN
CE 
TIME 2016 4 3 7 
2015 7 4 11 
2014 3 3 6 
2013 9 2 11 
2012 13 1 14 
2011 4 2 6 
Total 40 15 55 
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Chi-Square Tests 
 Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 6,308
a
 5 ,277 
Likelihood Ratio 6,882 5 ,230 
Linear-by-Linear Association 2,667 1 ,102 
N of Valid Cases 55   
a. 8 cells (66,7%) have expected count less than 5. The minimum 
expected count is 1,64. 
 
The associations of the completeness of reporting i) with the number of the participants randomized 
in each trial & ii) with the impact factor of the journal 
As far the association of completeness of reporting with the impact factor of the journal where the 
article was published is concerned, we found out that the impact factor does correlate positively with 
the reporting of checklists’ items. More specifically we found a positive R= 0.308 with possibility for 
error less than 5%, (p=0,032< 0, 5). However R-squared= 0,095, which mean that only 9, 5% of the 
variation of the reporting can be accounted for by the Impact Factor. Even so, we have proven that 
journals with higher Impact Factor, affect positively reporting. 
 
 
 
 
 
 
 
 The associations of the completeness of reporting i) with the number of the participants 
randomized in each trial & ii) with the impact factor of the journal 
 
o Pearson’s correlation for:  
 Compliance & Randomized Participants 
 Compliance & Impact Factor 
 Randomized Participants & Impact Factor 
o Linear Regression lines for  Randomized Participants, Impact Factor, Randomized 
Participants & Impact Factor 
o Adjusted correlations 
 
 
Correlations 
 Compliance 
Randomized_
participants 
Impact_Facto
r 
Compliance Pearson 
Correlation 
1 ,320* ,308* 
Sig. (2-tailed)  ,018 ,032 
N 55 54 49 
Randomized_participant
s 
Pearson 
Correlation 
,320* 1 ,375** 
Sig. (2-tailed) ,018  ,009 
N 54 54 48 
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Impact_Factor Pearson 
Correlation 
,308* ,375** 1 
Sig. (2-tailed) ,032 ,009  
N 49 48 49 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
Impact Factor 
 
 
ANOVAa 
Model 
Sum of 
Squares df Mean Square F Sig. 
1 Regression 1217,343 1 1217,343 4,912 ,032b 
Residual 11649,174 47 247,855   
Total 12866,517 48    
a. Dependent Variable: Compliance 
b. Predictors: (Constant), Impact_Factor 
 
 
 
 
 
 
Model Summary 
Model R R Square 
Adjusted R 
Square 
Std. Error of 
the Estimate 
1 ,308a ,095 ,075 15,74340 
a. Predictors: (Constant), Impact_Factor 
 
 
 
Randomized Participants 
 
ANOVAa 
Model 
Sum of 
Squares df Mean Square F Sig. 
1 Regression 1282,783 1 1282,783 5,915 ,018b 
Residual 11276,979 52 216,865   
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:04:59 EET - 137.108.70.7
28 | P a g e  
 
Total 12559,762 53    
a. Dependent Variable: Compliance 
b. Predictors: (Constant), Randomized_participants 
 
 
Model Summary 
Model R R Square 
Adjusted R 
Square 
Std. Error of 
the Estimate 
1 ,320a ,102 ,085 14,72634 
a. Predictors: (Constant), Randomized_participants 
 
 
 
Adjusted correlations for 1) Randomized Participants, 2) Impact Factor 
 
 
 
 
Correlations 
Control Variables Compliance 
Impact_Facto
r 
Randomized_participant
s 
Compliance Correlation 1,000 ,267 
Significance (2-
tailed) 
. ,070 
df 0 45 
Impact_Factor Correlation ,267 1,000 
Significance (2-
tailed) 
,070 . 
df 45 0 
 
 
Correlations 
Control Variables Compliance 
Randomized_
participants 
Impact_Factor Compliance Correlation 1,000 ,258 
Significance (2-
tailed) 
. ,080 
df 0 45 
Randomized_participant Correlation ,258 1,000 
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s Significance (2-
tailed) 
,080 . 
df 45 0 
 
 
 
Randomized Participants & Impact Factor 
 
 
 
ANOVAa 
Model 
Sum of 
Squares df Mean Square F Sig. 
1 Regression 2264,535 2 1132,268 5,327 ,008b 
Residual 9565,005 45 212,556   
Total 11829,540 47    
a. Dependent Variable: Compliance 
b. Predictors: (Constant), Impact_Factor, Randomized_participants 
 
 
 
 
 
Comparison of the CONSORT items reported with (>75%) compliance each year 
 
Year * (>75%)compliance Crosstabulation 
Count   
 
(>75%)compliance 
Total NO YES 
Year 2011 45 10 55 
2012 41 14 55 
2013 41 14 55 
2014 36 19 55 
2015 39 16 55 
2016 38 17 55 
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Total 240 90 330 
 
 
Chi-Square Tests 
 Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 4,400
a
 5 ,493 
Likelihood Ratio 4,522 5 ,477 
Linear-by-Linear Association 2,763 1 ,096 
N of Valid Cases 330   
a. 0 cells (0,0%) have expected count less than 5. The minimum 
expected count is 15,00. 
 
 
Comparison of  the Compliance of “5 key methodological factors” between two time periods (May 2001-
2013) & (2014-May 2016) 
 
MANOVA-Hotelling’s test 
 
Multivariate Tests
a
 
Effect Value F Hypothesis df Error df Sig. 
Partial Eta 
Squared 
Intercept Pillai's Trace 1,000 14722,830
b
 4,000 1,000 ,006 1,000 
Wilks' Lambda ,000 14722,830
b
 4,000 1,000 ,006 1,000 
Hotelling's Trace 58891,322 14722,830
b
 4,000 1,000 ,006 1,000 
Roy's Largest Root 58891,322 14722,830
b
 4,000 1,000 ,006 1,000 
Time_Period Pillai's Trace ,999 387,095
b
 4,000 1,000 ,038 ,999 
Wilks' Lambda ,001 387,095
b
 4,000 1,000 ,038 ,999 
Hotelling's Trace 1548,381 387,095
b
 4,000 1,000 ,038 ,999 
Roy's Largest Root 1548,381 387,095
b
 4,000 1,000 ,038 ,999 
a. Design: Intercept + Time_Period 
b. Exact statistic 
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